In the article titled "Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review" [1] , there was an error in the second and third affiliations. e corrected affiliations are shown above.
In the "4.2. Corticosteroid erapy with Sustained Delivery System" subsection, the following should be updated:
(1) e text reading "It has been reported by a FAME study that low dose of Iluvien inserted (0.19 mg per day) showed improved BCVA compared to higher dose [14, 15, 39] . Currently, Iluvien is still under investigation by FDA to approve its application to the market [13]" should be corrected to "It has been reported by a FAME study that low dose of Iluvien inserted (0.2 mg per day) showed improved BCVA compared to higher dose [14, 15, 39] . At 3 years in the FAME trials, Iluvien (0.2 µg fluocinolone acetonide per day) led to 28.7% of patients achieving a ≥15 letter score improvement in visual acuity versus 18.9% in the sham group. is effect was even greater in a preplanned analysis of the data assessing the impact in patients with persistent or recurrent diabetic macular edema (DME) and in this group Iluvien led to 34.0% achieving a ≥15 letter score improvement versus 13.4% in the sham group. Based on the results of the FAME pivotal trials, Iluvien is now approved for use in DME in Europe and the USA." 
